The Alzheimer’s Drug Discovery Foundation (ADDF) announces the release of its 2016 Annual Report. The report, titled “From Idea to Impact,” details the progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.
Mark Roithmayr, CEO of the ADDF, says, “’From Idea to Impact’ is the heart of what we do. It starts with an idea in the head of a researcher, which is developed over years into a drug. The ADDF supports that development, ensuring that good ideas can impact the lives of patients who need them.”
The report includes an overview of every program the ADDF supported in 2016, indicating stage of development and intended target. As Dr. Howard Fillit explains in his opening letter, having many targets is critical. “Our strategic investments have resulted in a diverse portfolio of drugs in clinical trials, which increases our chances of success.”
In the report, the ADDF showcases funded programs that have reached clinical trials, the final stages of a drug’s development. The featured drug programs come from: M3 Biotechnologies, Vanderbilt University, Georgetown University Medical Center, and Agenebio.
The report also includes an overview of the ADDF’s financial statements, highlights from its events, and a complete listing of its donors.